Atlas Trials

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Clinical trial NCT05652283 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05652283
Sponsor
Bai-Rong Xia
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2022-11-06
Primary completion
2024-05-31
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.